Tag: Drug-eluting technology

VAM discussion on latest paclitaxel meta-analysis yields mix of caution, skepticism

A Vascular Annual Meeting (VAM) sponsored session on paclitaxel safety drew a mix of skeptical and cautious responses to the latest meta-analysis from interventional...

PRISTINE registry with Selution SLR sirolimus drug-eluting balloon completes enrollment

MedAlliance has announced completion of patient enrollment in the PRISTINE clinical trial with the Selution SLR 018 drug-eluting balloon (DEB) for the treatment of patients with below-the-knee...

Postmarket study of sirolimus-eluting balloon enrolls first patient

MedAlliance has announced enrollment of the first patient in SUCCESS PTA, its large post-market study with the drug-eluting balloon Selution SLR for the treatment...

Veterans study: No evidence of increased risk of death with use...

A study of more than 10,000 U.S. veterans with peripheral arterial disease (PAD) undergoing endovascular interventions in the femoropopliteal segment found that rates of...

MHRA: Warning to be added to paclitaxel device IFUs in Europe

In a new field safety notice, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) states that a warning and clinical summary section will be...
Richard Neville

Drug-coated technology question aired during SAVS opening session

PALM BEACH, Fla.—Discussion of the drug-coated technology issue was piqued during the opening session of the Southern Association for Vascular Surgery (SAVS) annual meeting...